Stereotactic radiotherapy for prostate cancer: A review and future directions

Table 1 Summary of stereotactic body radiotherapy prostate trials and retrospective analyses

Study	No. of patients	Dose	Median follow-up	Biochemical RFS	Overall survival	PSA response	BF1	PSA bounce
Madsen (IJROBP, 2007)	40	6.7 Gy × 5 Fx	41 mo	90% at 48 mo		18 mo time to nadir	3	“Few"
Pham (IJROBP, 2010)	40	6.7 Gy × 5 Fx	60 mo	93% at 60 mo	75% at 60 mo	Median nadir of 0.65 ng/mL at median time of 24 mo		22.50%
Boike (JCO, 2011)	15/15/15 (45 tot)	9/9.5/10 Gy × 5 Fx	30/18/12 mo	100% at median follow-up	100% at median follow-up	Mean < 0.4 ng/mL at 12 mo for all cohorts	0	"Multiple"
Katz (BMC Urol, 2010)	50/254 (304 tot)	7/7.25 Gy × 5 Fx	30/17 mo	35 Gy: 88% < 1 ng/mL PSA at 30 mo 36.25 Gy: 81% < 1 ng/mL PSA at 24 mo2	94%/99% at median follow-up. No deaths due to prostate cancer	28.1% < 0.5 ng/mL at 12 mo	4	37
Jabarri (IJROBP, 2012)	20/18 (38 tot)	9.5 Gy × 4/2 Fx	18.1/23.5 mo	100% at median follow-up		Median of 0.35 ng/mL at 18.3 mo	0
King (IJROBP, 2012)	67	7.25 Gy × 5 Fx	2.7 yr	94% at 4 yr		Median of 0.50 ng/mL at follow-up	2
McBride (Cancer, 2012)	34/10/1 (45 tot)	7.5/7.25 Gy × 5 Fx, 1 received "other regimen"	44.5 mo	95.5%/97.5% at 3 yr	97.7% at 3 yr	Median of 0.2 ng/mL at follow-up	0	9
Anwar (Rad Oncol, 2016)	24/26 (50 tot)	9.5/10.5 Gy boost in 2 Fx	42.7 mo	95%/95%/90% at 3/4/5 yr		Median nadir of 0.05 ng/mL at median time of 26.2 mo	4	2
Mantz (Fontiers Rad Oncol, 2014)	102	8 Gy × 5 Fx	Min. of 5 yr	99% at 6 yr		Mean of 0.27 ng/mL at 24 mo	1	15
Hannan (Eur J Cancer, 2016)	92	9/9.5/10 Gy × 5 Fx	54 mo (pooled phase I/II)	98.6% at 5 yr	94%/89.7% at 3/5 yr	Median of 0.125 ng/mL at 42 mo	1	19
Freeman (Rad Oncol, 2011)	41	7-7.25 Gy × 5 Fx	5 yr	93% at 5 yr		Median nadir of 0.3 ng/mL at follow-up	3
Davis (Cureus, 2015)	437	7-7.4 Gy × 5 Fx, 9.5 Gy × 4 Fx, 19.5-29 Gy boost	20 mo	96.1% combined at 2 yr 99.0%/94.5%/89.8% for low/intermediate/high-risk at 2 yr		Median of 0.4 ng/mL at 24 mo	15	35

¹Biochemical failure;

²Values reflect only patients who did not receive hormone therapy.